Bifidobacterium breve VPro 52 and Similar Frequency of Adverse Events

• Infant formula containing galacto-and fructo-oligosaccharides and Bifidobacterium breve M-16V supports adequate growth and tolerance in healthy infants in a randomised, controlled, double-blind, prospective, multicentre study

  • 2019-11-20
  • RCT · n = 359
  • Journal of Nutritional Science 5
  • • M. Abrahamse-Berkeveld
    • M. Alles
    • E. Franke-Beckmann
    • K. Helm
    • R. Knecht
    • R. Köllges
    • B. Sandner
    • J. Knol
    • K. Ben Amor
    • A. Bufe

  • PubMed: 28620469
  • DOI: 10.1017/jns.2016.35

  9 Insights on

  • Similar Frequency of Adverse Events

  • High evidence
  • Large Human Trial

  The number of adverse events was not different between both groups.

  Effect

  Neutral

  Effect size

  Moderate

  Significant

  No